Blood-based biomarker assays for personalised tumour therapy: value of latest circulating biomarkers Thomas Schlange, Bayer HealthCare Need for public-private

First Page		Document Content
Date: 2014-01-09 11:14:02 Biomarkers Biotechnology Chemical pathology European Federation of Pharmaceutical Industries and Associations Circulating tumor cell Medicine Biology Biomarker		Blood-based biomarker assays for personalised tumour therapy: value of latest circulating biomarkers Thomas Schlange, Bayer HealthCare Need for public-private Add to Reading List Source URL: www.imi.europa.eu Download Document from Source Website File Size: 875,90 KB Share Document on Facebook

	Press Release EBiSC – the first European bank for induced pluripotent stem cells Pharmaceutical companies who are members of the European Federation of Pharmaceutical Industries and Associations (EFPIA) join forces wi DocID: 1tXAK - View Document
	EFPIA Disclosure Code: Your Questions Answered March 2016 #pharmadisclosure www.efpia.eu DocID: 1rsSj - View Document
	European Federation of Biotechnology Microbial Physiology Section The 2007 Annual meeting of the EFB Microbial Physiology Section was held aton Monday 17th September during ECB13, Fira de Barcelona in Barcelona, DocID: 1rnG2 - View Document
	ABIRISK ABIRISK Project Officially Started A growing number of medicines are based on biological molecules such as proteins and monoclonal antibodies. These novel drugs have resulted in new, more effective treatments for DocID: 1rlyu - View Document
	About the EFPIA Disclosure Code Securing the future of collaboration between industry and healthcare professionals Collaboration between industry and healthcare professionals (HCPs) and healthcare organisations (HCOs) be DocID: 1rkGi - View Document